USANA Health Sciences (NYSE:USNA) CFO Sells $100,500.00 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) CFO G Doug Iiekking sold 5,360 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $18.75, for a total value of $100,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

USANA Health Sciences Trading Up 0.1%

NYSE USNA traded up $0.01 during mid-day trading on Thursday, reaching $18.81. 17,321 shares of the company’s stock traded hands, compared to its average volume of 125,246. USANA Health Sciences, Inc. has a 1-year low of $16.60 and a 1-year high of $38.32. The company has a fifty day simple moving average of $18.26 and a 200-day simple moving average of $19.47. The company has a market cap of $347.23 million, a price-to-earnings ratio of 40.02, a P/E/G ratio of 0.72 and a beta of 0.77.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.44 by $0.17. The company had revenue of $250.22 million during the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Equities research analysts forecast that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue boosted its position in USANA Health Sciences by 8.5% during the 4th quarter. State of Alaska Department of Revenue now owns 6,666 shares of the company’s stock worth $130,000 after acquiring an additional 525 shares during the period. Russell Investments Group Ltd. boosted its position in USANA Health Sciences by 4.6% during the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock worth $244,000 after acquiring an additional 542 shares during the period. Quantbot Technologies LP boosted its position in USANA Health Sciences by 19.5% during the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after acquiring an additional 646 shares during the period. Intech Investment Management LLC boosted its position in USANA Health Sciences by 13.5% during the 3rd quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock worth $213,000 after acquiring an additional 918 shares during the period. Finally, National Bank of Canada FI boosted its position in USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after acquiring an additional 1,201 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on USNA. Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Friday, March 27th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, USANA Health Sciences currently has an average rating of “Reduce”.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.